Rigel Pharmaceuticals | RIGL - DEBITO





DEBITO Cambiamento Data
Agenus USD 35.54M 2.34M 2025-03
Amgen USD 57.3B 19M 2026-06
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 983.69M 5.77M 2026-06
AstraZeneca USD 32.24B 1.68B 2026-06
BioMarin Pharmaceutical USD 4.19B 11.99M 2026-09
Bristol-Myers Squibb USD 42.88B 2.18B 2026-09
Celldex Therapeutics USD 4.9M 3M 2026-06
Daiichi Sankyo JPY 500.48B 200B 2026-06
Eli Lilly USD 54.91B 11.54B 2026-06
Halozyme Therapeutics USD 2.15B 2.02M 2026-06
Heron Therapeutics USD 149.65M 157K 2024-09
Intrexon USD 0 13.82M 2024-06
Ionis Pharmaceuticals USD 1.77B 141M 2026-09
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Ligand Pharmaceuticals USD 1.13B 679.48M 2026-06
MacroGenics USD 35.09M 1.42M 2026-06
Neurocrine Biosciences USD 392.3M 9.5M 2026-09
Pfizer USD 62.67B 523M 2026-09
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
Sangamo BioSciences USD 0 0 2022-06
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Veracyte USD 40.11M 774K 2026-06